Mbx Biosciences, INC Form 4 insider transactions

Carl L. Gordon, a director of MBX Biosciences, acquired stock options for 15,963 shares at an exercise price of $16 on September 12, 2024.

Director Steven Ryder of MBX Biosciences acquired stock options for 15,963 shares on September 12, 2024.

Richard Bartram, CFO of MBX Biosciences, acquired stock options for 42,578 shares of common stock on September 12, 2024.

Salomon Azoulay, Chief Medical Officer of MBX Biosciences, acquired stock options for 45,011 shares of common stock on September 12, 2024.

Director Edward T. Mathers acquired stock options for 15,963 shares of MBX Biosciences, Inc. on September 12, 2024.

P. Kent Hawryluk, President & CEO of MBX Biosciences, acquired stock options for 120,436 shares on September 12, 2024.

Director Aynechi Tiba of MBX Biosciences acquired stock options for 15,963 shares on September 12, 2024.

Director Patrick J. Heron acquired 15,963 stock options in MBX Biosciences, Inc. on September 12, 2024.

James M. Cornelius, a director of MBX Biosciences, acquired stock options for 15,963 shares on September 12, 2024.

Director Ora H. Pescovitz acquired 15,963 stock options in MBX Biosciences, Inc. on September 12, 2024, at an exercise price of $16.